Airway Therapeutics Closes $50 Million Equity Round to Advance Late-Stage Development of Zelpultide Alfa

ATLANTA, Aug. 25, 2026 /PRNewswire/ -- Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced the closing of a $50 million equity round to support the

Raccontata daadnkronos.com